You are here: Industry Insights > AstraZeneca

News List

AstraZeneca chalks up double Japanese approval in lung and breast cancer pharmafile
July 06, 2018
First up, Imfinzi (durvalumab) has been authorised as maintenance therapy after definitive chemoradiation therapy (CRT) for the treatment of locally-advanced
AstraZeneca receives DCG(I) nod for Durvalumab in India financialexpress
June 29, 2018
AstraZeneca Pharma India Limited (AZPIL) has received Import & Market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General India, DCG(I). The receipt of this permission paves way for the launch of durvalumab (ImfinziTM) in India,
AstraZeneca, Merck eye $1 billion boost from cancer drug success financialexpress
June 29, 2018
The result should pave the way for expanded use of the medicine, which is being developed and marketed with Merck & Co under a deal struck last year
Forget Tagrisso's $3B sales target. It'll be worth double that by 2023, analyst says fiercepharma
June 26, 2018
Recent approvals of Tagrisso in the first-line lung cancer setting have AstraZeneca management optimistic about the $3 billion sales target it set several years ago. But some analysts have higher hopes—and one just came up with a bullish estimate that's o
AstraZeneca, Eli Lilly scrap Alzheimer’s treatment trial financialexpress
June 14, 2018
AstraZeneca and Eli Lilly have announced the ending of a large clinical trial of treatment for Alzheimer’s that they had been developing together.
AstraZeneca receives EU nod for lung cancer drug Tagrisso biospectrumasia
June 13, 2018
Tagrisso is a monotherapy for the 1st-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer
Zai Lab appoints AstraZeneca's William Liang as CCO biospectrumasia
June 13, 2018
Prior to joining Zai Lab, William served as Vice President at AstraZeneca heading up the Oncology Business Unit in China
AstraZeneca receives European clearance for lung cancer drug SHARE pharmaceutical-technology
June 13, 2018
AstraZeneca has secured marketing clearance from the European Commission (EC) for its Tagrisso (osimertinib) drug to treat non-small cell lung cancer (NSCLC) in adults.
Zai Lab grabs top AstraZeneca cancer executive to prep its first drug rollout fiercepharma
June 06, 2018
China’s Zai Lab is revving up for its first drug launch, and it's brought on an AstraZeneca oncology executive to lead the charge.
AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline worldpharmanews
June 05, 2018
AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page